TW202128200A - 誘導或增強經法尼醇x受體（fxr）介導之轉錄反應的方法 - Google Patents

誘導或增強經法尼醇x受體（fxr）介導之轉錄反應的方法 Download PDF

Info

Publication number
TW202128200A
TW202128200A TW109140455A TW109140455A TW202128200A TW 202128200 A TW202128200 A TW 202128200A TW 109140455 A TW109140455 A TW 109140455A TW 109140455 A TW109140455 A TW 109140455A TW 202128200 A TW202128200 A TW 202128200A
Authority
TW
Taiwan
Prior art keywords
fxr
compound
subject
disease
composition
Prior art date
Application number
TW109140455A
Other languages
English (en)
Chinese (zh)
Inventor
永齊 鄭
嶸 林
Original Assignee
耶魯大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 耶魯大學 filed Critical 耶魯大學
Publication of TW202128200A publication Critical patent/TW202128200A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
TW109140455A 2019-11-20 2020-11-19 誘導或增強經法尼醇x受體（fxr）介導之轉錄反應的方法 TW202128200A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962937964P 2019-11-20 2019-11-20
US62/937,964 2019-11-20

Publications (1)

Publication Number Publication Date
TW202128200A true TW202128200A (zh) 2021-08-01

Family

ID=75981072

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109140455A TW202128200A (zh) 2019-11-20 2020-11-19 誘導或增強經法尼醇x受體（fxr）介導之轉錄反應的方法

Country Status (7)

Country Link
US (1) US20220409631A1 (https=)
EP (1) EP4061377A4 (https=)
JP (1) JP2023502251A (https=)
KR (1) KR20220119367A (https=)
CN (1) CN114786678A (https=)
TW (1) TW202128200A (https=)
WO (1) WO2021102124A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI819307B (zh) * 2020-05-19 2023-10-21 吉亞生物科技股份有限公司 萜類化合物在治療或預防纖維化疾病中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9713605B2 (en) * 2011-11-18 2017-07-25 Simpson Biotech Co., Ltd. Ameliorative or preventive effect of Antrodia cinnamomea in arthritis, cartilage destruction, or chondrocyte death
CN103159732A (zh) * 2011-12-15 2013-06-19 台湾利得生物科技股份有限公司 一种聚乙炔化合物、含其中的萃取物及其应用
JP2014139153A (ja) * 2012-08-24 2014-07-31 Taiwan Antitumer Biotech Co Ltd 腫瘍の治療及び／又は予防における抗がん薬と組み合わせたアントシン誘導体
WO2015065983A1 (en) * 2013-10-29 2015-05-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of gastrointestinal infections
CN104606260B (zh) * 2014-12-25 2018-01-30 恩扬生物科技股份有限公司 牛樟芝子实体萃取物用于改善化疗副作用的用途
TWI623749B (zh) * 2015-04-30 2018-05-11 吳永昌 一種樟芝萃取物製備及分析方法
CN105311036B (zh) * 2015-11-26 2017-11-21 中国农业大学 樟芝酸h在防治药物性肝损伤中的应用

Also Published As

Publication number Publication date
EP4061377A4 (en) 2023-11-29
CN114786678A (zh) 2022-07-22
JP2023502251A (ja) 2023-01-23
EP4061377A1 (en) 2022-09-28
US20220409631A1 (en) 2022-12-29
KR20220119367A (ko) 2022-08-29
WO2021102124A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
CN114641293A (zh) 一种fgfr抑制剂的用途
US20130316994A1 (en) Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
RU2644635C2 (ru) Системы, способы и составы для лечения рака
US20250367229A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
TW201545744A (zh) 治療胰臟癌之醫藥配方及其應用
US20110160170A1 (en) Compositions and methods of inducing endoplasmic reticulum stress response
Kooybaran et al. Esophageal lichen planus successfully treated with the JAK1/3 inhibitor tofacitinib
TW201247612A (en) Compositions for treating kidney disorders
Girod et al. The COX inhibitors indomethacin and meloxicam exhibit anti-emetic activity against cisplatin-induced emesis in piglets
Tang et al. Tetrahydroberberrubine exhibits preventive effect on obesity by activating PGC1α-mediated thermogenesis in white and brown adipose tissue
TW202128200A (zh) 誘導或增強經法尼醇x受體（fxr）介導之轉錄反應的方法
US11628176B2 (en) Combinational drug therapies
CN111346081A (zh) 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
Wen et al. Bromelain improves decrease in defecation in postoperative rats: Modulation of colonic gene expression of inducible nitric oxide synthase
KR101901001B1 (ko) PPAR-β 길항제를 포함하는 항암 효과 증진용 약학적 조성물
WO2024230460A1 (zh) 五环三萜结构修饰化合物在制备白癜风药物中的应用及新制剂
CN115607546A (zh) Isarubrolone C、包含Isarubrolone C的药物组合物及应用
CN115778944A (zh) 蛇床子素在制备改善或治疗认知功能障碍的药物中的用途
CN116549455A (zh) PLK4抑制剂Centrinone在制备治疗包虫病药物中的应用
CN111281866B (zh) 一种预防或治疗溃疡性结肠炎的中药化学制剂
HK40077325A (en) Methods of inducing or enhancing farnesoid x receptor (fxr)-mediated transcriptional response
WO2022121356A1 (zh) 组合物及其在提高维生素c抗肿瘤效果中的用途
JP2005538098A (ja) ヘムオキシゲナーゼレベルの上昇を必要とする治療上の処置におけるレインの使用
AU2017101212A4 (en) Method of selectively inhibiting mpges-1